Setback for Pfizer and BMS clotting drug

pharmafile | September 5, 2008 | News story | Sales and Marketing BMS, Pfizer, clot, cv 

Related Content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …

Elekta and BMS partner for digital treatment for melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

Latest content